PMID- 31199997
OWN - NLM
STAT- MEDLINE
DCOM- 20200218
LR  - 20200218
IS  - 1096-0295 (Electronic)
IS  - 0273-2300 (Linking)
VI  - 107
DP  - 2019 Oct
TI  - Assessment of hypolipidemic, anti-inflammatory and antioxidant properties of 
      medicinal plant Erica multiflora in triton WR-1339-induced hyperlipidemia and 
      liver function repair in rats: A comparison with fenofibrate.
PG  - 104404
LID - S0273-2300(19)30166-7 [pii]
LID - 10.1016/j.yrtph.2019.104404 [doi]
AB  - Hyperlipidemia is a serious health threat that has been linked to oxidative 
      stress and systemic inflammation, causing among many other disorders essentially 
      liver disease. The current study was conducted to evaluate the 
      antihyperlipidemic, antioxidant and anti-inflammatory potential of methanol leaf 
      extract from Erica multiflora (M-EML). Triton WR-1339-induced hyperlipidemic rats 
      were divided into six groups: control group (CG), hyperlipidemic group (300 mg/kg 
      body weight "BW") (HG), hyperlipidemic group treated with M-EML (150 and 
      250 mg/kg) (HG + M-EML), normal rats treated with M-EML (250 mg/kg) and 
      fenofibrate-treated group (HG + FF) (65 mg/kg). After 24 h of administration, 
      triton WR-1339 induced a significant increase in lipid profile, atherogenic index 
      (AI) and Coronary Risk Index (CRI) in HG group compared to control group. 
      Furthermore, triton WR-1339 administration induced alteration in the status of 
      pro-inflammatory markers (aspartate transaminase, alanine transaminase, IFN-gamma and 
      Nitric oxide production). HG group showed also, a high level of lipid 
      peroxidation, an altered antioxidant enzyme profiles and an increase in DNA 
      damages, in liver. However, orally administration of M-EML mitigates 
      significantly these disorders, proving hence a protective potential against 
      triton WR-1339-induced hyperlipidemia. These findings suggest that M-EML extract 
      could be used as functional foods and natural adjuvant treatment of 
      hyperlipidemia.
CI  - Copyright (c) 2019. Published by Elsevier Inc.
FAU - Khlifi, Rihab
AU  - Khlifi R
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia; Higher Institute of Biotechnology of Monastir, University of Monastir, 
      Avenue Tahar Hadded, BP 74, 5000, Monastir, Tunisia. Electronic address: 
      rihabkhlifi@gmail.com.
FAU - Lahmar, Aida
AU  - Lahmar A
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia; Faculty of Pharmacy, University of Monastir, Avicenna Street, 5000, 
      Monastir, Tunisia.
FAU - Dhaouefi, Zaineb
AU  - Dhaouefi Z
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia; Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, 
      Tunisia.
FAU - Kalboussi, Zahar
AU  - Kalboussi Z
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia; Faculty of Pharmacy, University of Monastir, Avicenna Street, 5000, 
      Monastir, Tunisia.
FAU - Maatouk, Mouna
AU  - Maatouk M
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia; Faculty of Pharmacy, University of Monastir, Avicenna Street, 5000, 
      Monastir, Tunisia.
FAU - Kilani-Jaziri, Soumaya
AU  - Kilani-Jaziri S
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia; Faculty of Pharmacy, University of Monastir, Avicenna Street, 5000, 
      Monastir, Tunisia.
FAU - Ghedira, Kamel
AU  - Ghedira K
AD  - Faculty of Pharmacy, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia.
FAU - Chekir-Ghedira, Leila
AU  - Chekir-Ghedira L
AD  - Unity of Bioactive and Natural Substances and Biotechnology UR17ES49, Faculty of 
      Dental Medicine, University of Monastir, Avicenna Street, 5000, Monastir, 
      Tunisia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20190611
PL  - Netherlands
TA  - Regul Toxicol Pharmacol
JT  - Regulatory toxicology and pharmacology : RTP
JID - 8214983
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Phytochemicals)
RN  - 0 (Plant Extracts)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - U202363UOS (Fenofibrate)
RN  - Y27PUL9H56 (tyloxapol)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemistry/*therapeutic use
MH  - Antioxidants/chemistry/*therapeutic use
MH  - *Ericaceae
MH  - Fenofibrate/therapeutic use
MH  - Hyperlipidemias/chemically induced/*drug therapy
MH  - Hypolipidemic Agents/chemistry/*therapeutic use
MH  - Liver/drug effects
MH  - Male
MH  - Phytochemicals/analysis/therapeutic use
MH  - Plant Extracts/chemistry/*therapeutic use
MH  - Plant Leaves
MH  - Polyethylene Glycols
MH  - Rats, Wistar
OTO - NOTNLM
OT  - Cardiovascular problems
OT  - Erica multiflora
OT  - Lipid profile
OT  - Liver functions
OT  - Triton WR-1339
EDAT- 2019/06/15 06:00
MHDA- 2020/02/19 06:00
CRDT- 2019/06/15 06:00
PHST- 2019/02/12 00:00 [received]
PHST- 2019/05/09 00:00 [revised]
PHST- 2019/06/10 00:00 [accepted]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2020/02/19 06:00 [medline]
PHST- 2019/06/15 06:00 [entrez]
AID - S0273-2300(19)30166-7 [pii]
AID - 10.1016/j.yrtph.2019.104404 [doi]
PST - ppublish
SO  - Regul Toxicol Pharmacol. 2019 Oct;107:104404. doi: 10.1016/j.yrtph.2019.104404. 
      Epub 2019 Jun 11.